Infinium Pharmachem Limited IPO
i. Infinium Pharmachem was incorporated with the objective of manufacturing and supplying of various pharma related chemicals, bulk drugs, pharma intermediates etc. Accordingly, the Company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs).
ii. The Company penetrated the Pharmaceutical market with the CRAMS Model i.e. Contract Research & Manufacturing Services in which the Company emphasizes on:
– Process Optimization;
– Developing / Manufacturing the products specifically as per customer’s requirement and final application;
– Customized Packing / Labelling;
– Reliable Supply of final product;
– Highly focused to Iodine Chemistry.
iii. Today, the Company’s manufacturing capabilities and technical expertise have efficiently catered numerous industries such as Pharmaceutical & Biotech, Specialty & Performance Chemicals, Agrochemicals, Human Health, Animal Health, Cosmetics, Sanitation, Electrical, Electronics and much more.
iv. The Company currently provides the widest range of Iodine derivatives in the market, with more than 250+ intermediates and 15+ APIs.
v. The Company has developed and maintained long – term healthy relationships with all its clients, including Pharmaceutical, Biotech and Fine Chemical companies and its products reach out to over 250+ clients globally. The Company also formed a foreign Subsidiary as a Joint Venture (JV) with Shanghai Witofly Chemical Co. Ltd., in the name of Shanghai Tajilin Industrial Co. Ltd., in the People’s Republic of China in the year 2019.
Objects of the Infinium Pharmachem Limited IPO:
Infinium Pharmachem Limited IPO Details:
|Open Date:||Mar 31 2023|
|Close Date:||Apr 05 2023|
|Face Value:||₹ 10 Per Equity Share|
|Issue Type:||Fixed Price Issue IPO|
|Issue Size:||25.31 Cr.|
|Lot Size:||1000 Shares|
|Issue Price:||₹ 135 Per Equity Share|
|Listing At:||NSE Emerge|
|Listing Date:||Apr 17 2023|
Promoters And Management:
Financials of Infinium Pharmachem Limited IPO:
|Particulars (in Lakhs)||2022||2021||2020|
|Revenue From Operations||9,912||7,053||3,884|
|Purchase of Stock-In-Trade||2,414||1,593||287|
|Change in Inventories||-162||-306||-104|
|Employees Benefit Expenses||354||275||209|
Comparison With Peers:
|Name of the Companies||Revenue (Cr)||Profit (Cr)||EPS||P/E||CMP||MCap|
|Infinium Pharmachem Limited||159||11||14||9.64||135||91|
|Samrat Pharmachem Limited||302||24||78.9||5.23||411||127|
Recommendation on Infinium Pharmachem Limited IPO:
Review and Recommendation of Infinium Pharmachem IPO by IZ team is 6/10 1. The Company is dealing specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs). The Company currently provides the widest range of Iodine derivatives in the market, with more than 250+ intermediates and 15+ APIs 2. They have a manufacturing plant in Gujarat. 3. The Company undertakes Contract Research and Manufacturing Services (CRAMS) to provide customized and fully confidential solutions to its clients. 4. The Company has developed and maintained long - term healthy relationships with all its clients, including Pharmaceutical, Biotech and Fine Chemical companies and its products reach out to over 250+ clients globally. 5. Revenue of the company has increased from 38 Crores in FY20 to ~100 Crores in Fy22. 6. The EBITDA Margins have grown from 7.87% to 11% in the last 3 years. 7. PAT has increased from 93 lac in FY20 to 6 Crores in Fy22. 8. Company is raising 25 Cr funds to meet marketing expenses, payment of debt, expansion of existing unit, and working capital requirement. 9. Company has healthy ROCE of 25% and ROE of 24%. 10. Asking P/E based on FY23 annualised earnings is 9.63x.